Poltreg S.A. (WSE:PTG)

Poland flag Poland · Delayed Price · Currency is PLN
26.00
-0.50 (-1.89%)
Jan 23, 2026, 4:24 PM CET
-32.64%
Market Cap123.58M
Revenue (ttm)n/a
Net Income (ttm)-24.56M
Shares Out4.66M
EPS (ttm)-5.27
PE Ration/a
Forward PE51.49
Dividendn/a
Ex-Dividend Daten/a
Volume2,720
Average Volume5,330
Open26.20
Previous Close26.50
Day's Range25.40 - 26.20
52-Week Range22.70 - 41.70
Beta0.73
RSI54.05
Earnings DateApr 16, 2026

About Poltreg

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 33
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PTG
Full Company Profile

Financial Performance

In 2024, Poltreg's revenue was 350,000, a decrease of -74.98% compared to the previous year's 1.40 million. Losses were -18.71 million, 38.1% more than in 2023.

Financial Statements